Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Populations news

Show

From To
Undocumented migrants more likely to be lost to follow-up and have poor virological outcomes after starting ART, Milan study confirms

Undocumented migrants living with HIV have especially poor rates of retention in care and virological suppression after starting antiretroviral therapy (ART), investigators from Italy report

Published
09 May 2017
By
Michael Carter
Where harm reduction policies went up, hepatitis C incidence went down, study finds

In a study tracking numbers of new infections of hepatitis C and rates of sharing syringes among people injecting drugs over two and a half decades, differences in infection trends emerged across cities in North America, Australia and the Netherlands, researchers report in a recent Clinical Infectious Diseases.

Published
09 May 2017
From
Science Speaks
On borrowed time

The delayed drug strategy – and lack of plan for an alcohol strategy – is pulling the lifeline from a sector in crisis, hears DDN

Published
08 May 2017
From
Drink & Drug News
Naloxone is a heath intervention that can’t be effectively provided without the knowledge and social connections of people who inject drugs

Programmes to provide naloxone, a drug that reverses the effects of opiate overdose, are successful because they harness the social contexts of drug use and

Published
05 May 2017
By
Roger Pebody
Fear of stigma is prompting young South Africans to seek early HIV treatment

Young South Africans are strongly motivated to seek HIV testing and treatment by a desire to maintain a healthy physical appearance and to appear normal

Published
04 May 2017
By
Keith Alcorn
HIV, Vaginal Sex and PrEP Initiation: What Should You Tell Your Patients or Clients?

This year, pre-exposure prophylaxis (PrEP) advocates noted a stunning disconnect between key organizations that issue guidelines on the use of tenofovir/emtricitabine (TDF/FTC, Truvada) for HIV prevention: The United States Centers for Disease Control and Prevention (CDC) continues to say that people need 20 days of daily TDF/FTC before they can consider themselves protected from vaginal HIV exposure -- but the World Health Organization (WHO) has stated that just seven days of the drug is enough.

Published
03 May 2017
From
The Body Pro
Increased screening for syphilis boosts detection of early latent infections among Australian gay men

Increased syphilis testing among gay men increased detection of early latent infections and was accompanied by a fall in the proportion of cases involving secondary syphilis, investigators report

Published
03 May 2017
By
Michael Carter
Fentanyl, the Drug Deadlier Than Heroin, Has Reached the UK

Everything you need to know about the drug that has already caused a spate of fatal overdoses.

Published
02 May 2017
From
Vice
Nelly Mugo—rolling out PrEP in Kenya

Nelly Mugo has had a central role in building evidence for PrEP, as a co-author on the Partners PrEP study. Most of her current work is focused on scale-up and roll-out of PrEP.

Published
28 April 2017
From
The Lancet (free registration required)
Healing Austin, Indiana: How town raced to stop America's worst rural HIV plague (three-part series)

Critics say Mike Pence was slow to react as a festering blight, then HIV gripped Austin, Indiana. This tiny city off Interstate 65 is the epicenter of a medical disaster. Dr. Tom Frieden, former director of the U.S. Centers for Disease Control and Prevention, confirms Austin contains the largest drug-fueled HIV outbreak to hit rural America in recent history, and "the largest concentrated outbreak ever documented in the United States."

Published
24 April 2017
From
Kentucky Courier-Journal

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.